In accordance with various aspects of the invention, CXCR4 agonists may be used to treat bone marrow progenitor or stem cells to reduce the susceptibility of the cells to cytotoxic agents. CXCR4 agonists may be used to treat bone marrow progenitor cells or stem cells to reduce the rate of cellular multiplication . CXCR4 agonists may be used to treat cancer in a mammal in conjunction with one or more cytotoxic agents. Cytotoxic agents may for example include chemotherapeutic agents or radiation. CXCR4 agonists may be used therapeutically to regulate bone marrow progenitor or stem cell growth in human diseases, such as cancer.
申请公布号
CA2335109(A1)
申请公布日期
2001.10.12
申请号
CA20012335109
申请日期
2001.02.23
申请人
CHEMOKINE THERAPEUTICS CORPORATION;THE UNIVERSITY OF BRITISH COLUMBIA
发明人
CASHMAN, JOHANNE;SALARI, HASSAN;TUDAN, CHRISTOPHER R.;EAVES, CONNIE J.;CLARK-LEWIS, IAN;SAXENA, GEETA;MERZOUK, AHMED